Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.

Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5342 Protocol Team .

Open Forum Infect Dis. 2018 Oct 20;5(10):ofy242. doi: 10.1093/ofid/ofy242. eCollection 2018 Oct.

2.

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring.

Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM; MTN-015; MTN-020/ASPIRE Study Teams.

Clin Infect Dis. 2018 Oct 22. doi: 10.1093/cid/ciy909. [Epub ahead of print]

PMID:
30346511
3.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

PMID:
29847509
4.

Subclinical herpesvirus shedding among HIV-1-infected men on antiretroviral therapy.

Agudelo-Hernandez A, Chen Y, Bullotta A, Buchanan WG, Klamar-Blain CR, Borowski L, Riddler SA, Rinaldo CR, Macatangay BJC.

AIDS. 2017 Sep 24;31(15):2085-2094. doi: 10.1097/QAD.0000000000001602.

5.

Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Chappell CA, Lamorde M, Nakalema S, Chen BA, Mackline H, Riddler SA, Cohn SE, Darin KM, Achilles SL, Scarsi KK.

AIDS. 2017 Sep 10;31(14):1965-1972. doi: 10.1097/QAD.0000000000001591.

6.

HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.

Riddler SA, Husnik M, Ramjee G, Premrajh A, Tutshana BO, Pather A, Siva S, Jeenarain N, Nair G, Selepe P, Kabwigu S, Palanee-Phillips T, Panchia R, Mhlanga F, Levy L, Livant E, Patterson K, Elharrar V, Balkus J.

PLoS One. 2017 Jun 28;12(6):e0178594. doi: 10.1371/journal.pone.0178594. eCollection 2017.

7.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team.

PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr.

8.

Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN-015.

Riddler SA, Husnik M, Gorbach PM, Levy L, Parikh U, Livant E, Pather A, Makanani B, Muhlanga F, Kasaro M, Martinson F, Elharrar V, Balkus JE; MTN-015 Protocol Team for the Microbicide Trials Network.

HIV Clin Trials. 2016 Sep;17(5):204-11. doi: 10.1080/15284336.2016.1212561. Epub 2016 Jul 28.

9.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

PMID:
27090986
10.

Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.

Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA; MTN-003B Protocol Team.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94. doi: 10.1097/QAI.0000000000000858.

11.

Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.

Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, Rinaldo CR.

J Infect Dis. 2016 May 1;213(9):1400-9. doi: 10.1093/infdis/jiv582. Epub 2015 Dec 8.

12.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT, Mellors JW; ACTG A5276s Protocol Team.

J Infect Dis. 2016 Feb 15;213(4):556-60. doi: 10.1093/infdis/jiv433. Epub 2015 Sep 2.

13.

Factors associated with bone mineral density in healthy African women.

Mgodi NM, Kelly C, Gati B, Greenspan S, Dai JY, Bragg V, Livant E, Piper JM, Nakabiito C, Magure T, Marrazzo JM, Chirenje ZM, Riddler SA; MTN-003B Protocol Team.

Arch Osteoporos. 2015;10:206. doi: 10.1007/s11657-015-0206-7. Epub 2015 Feb 14.

14.

HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, Riddler SA, McMahon DK, Hong F, Mellors JW.

Clin Infect Dis. 2014 Nov 1;59(9):1312-21. doi: 10.1093/cid/ciu585. Epub 2014 Jul 29.

15.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

16.

Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.

Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch RJ, Riddler SA, Ellis RJ, Evans SR.

J Neurovirol. 2013 Dec;19(6):557-64. doi: 10.1007/s13365-013-0216-4. Epub 2013 Dec 3.

17.

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

Huang JS, Hughes MD, Riddler SA, Haubrich RH; Aids Clinical Trials Group A5142 Study Team.

HIV Clin Trials. 2013 Sep-Oct;14(5):224-34. doi: 10.1310/hct1405-224.

18.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM.

Clin Infect Dis. 2013 Dec;57(11):1607-17. doi: 10.1093/cid/cit595. Epub 2013 Sep 17.

19.

CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression.

Schuler PJ, Macatangay BJ, Saze Z, Jackson EK, Riddler SA, Buchanan WG, Hilldorfer BB, Mellors JW, Whiteside TL, Rinaldo CR.

AIDS. 2013 Jun 19;27(10):1545-55. doi: 10.1097/QAD.0b013e328360c7f3.

20.

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.

Etter P, Landovitz R, Sibeko S, Sobieszczyk ME, Riddler SA, Karg C, Tsibris A, Schouten J.

AIDS. 2013 Apr 24;27(7):1119-28. doi: 10.1097/QAD.0b013e32835dc08e. Review.

21.

Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL; International HIV Adaptation Collaborative.

J Virol. 2012 Dec;86(24):13202-16. doi: 10.1128/JVI.01998-12. Epub 2012 Oct 10.

22.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams.

AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20.

23.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e.

24.

Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes.

Almeida CA, Bronke C, Roberts SG, McKinnon E, Keane NM, Chopra A, Kadie C, Carlson J, Haas DW, Riddler SA, Haubrich R, Heckerman D, Mallal S, John M.

J Immunol. 2011 Sep 1;187(5):2502-13. doi: 10.4049/jimmunol.1100691. Epub 2011 Aug 5.

25.

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data.

Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, Haubrich RH.

Cost Eff Resour Alloc. 2011 May 8;9:5. doi: 10.1186/1478-7547-9-5.

26.

Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.

Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029.

27.

European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.

Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA.

AIDS. 2011 Jan 2;25(1):37-47. doi: 10.1097/QAD.0b013e32833f9d02.

28.

Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.

Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR.

PLoS One. 2010 Mar 24;5(3):e9852. doi: 10.1371/journal.pone.0009852.

29.

Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs.

John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D, Haas DW, Riddler SA, Haubrich R, Mallal S.

J Immunol. 2010 Apr 15;184(8):4368-77. doi: 10.4049/jimmunol.0903745. Epub 2010 Mar 15.

30.

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.

Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S.

PLoS One. 2009 Aug 19;4(8):e6687. doi: 10.1371/journal.pone.0006687.

31.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team.

AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.

32.

Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, Deeks SG, Landay AL, Riddler SA.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):135-9. doi: 10.1089/aid.2008.0200.

33.

Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.

Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo CR Jr, Riddler SA.

Clin Vaccine Immunol. 2009 Feb;16(2):233-40. doi: 10.1128/CVI.00066-08. Epub 2008 Nov 26.

34.

Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.

Riddler SA, Li X, Otvos J, Post W, Palella F, Kingsley L, Visscher B, Jacobson LP, Sharrett AR; Multicenter AIDS Cohort Study.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):281-8. doi: 10.1097/QAI.0b013e31817bbbf0.

PMID:
18545156
35.

Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.

36.

Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.

Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA.

Clin Vaccine Immunol. 2008 Feb;15(2):284-92. Epub 2007 Oct 17.

37.

A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.

Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA.

Antivir Ther. 2007;12(4):531-41.

PMID:
17668562
38.

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A.

HIV Med. 2007 Jul;8(5):280-7.

39.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA 3rd, Klingman KL, Gulick RM; ACTG A5166s Protocol Team.

J Infect Dis. 2007 Apr 15;195(8):1169-76. Epub 2007 Mar 6.

PMID:
17357053
40.

A novel pattern of lipoaccumulation in HIV-infected men.

Palella FJ Jr, Chmiel JS, Riddler SA, Calhoun B, Dobs A, Visscher B, Kingsley L.

JAMA. 2006 Aug 16;296(7):766-8. No abstract available.

PMID:
16905782
41.

In vitro and in vivo protein sampling by combined microdialysis and ultrafiltration.

Rosenbloom AJ, Ferris RL, Sipe DM, Riddler SA, Connolly NC, Abe K, Whiteside TL.

J Immunol Methods. 2006 Feb 20;309(1-2):55-68. Epub 2005 Dec 27. Erratum in: J Immunol Methods. 2006 Jun 30;313(1-2):219. Ferris, R [corrected to Ferris, RL].

PMID:
16414066
42.

Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches.

Connolly NC, Riddler SA, Rinaldo CR.

AIDS Rev. 2005 Jul-Sep;7(3):168-80. Review.

PMID:
16302465
43.

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS.

AIDS. 2005 Sep 2;19(13):1375-83.

PMID:
16103768
44.

Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection.

Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):620-5.

PMID:
16044017
45.

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.

Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS.

Arch Intern Med. 2005 May 23;165(10):1179-84. Erratum in: Arch Intern Med. 2005 Nov 28;165(21):2541.

PMID:
15911733
46.

Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP; Multicenter AIDS Cohort Study.

AIDS. 2005 Jun 10;19(9):953-60.

PMID:
15905677
47.

Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

Li X, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, Jacobson LP.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):320-8.

PMID:
15735452
48.

Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study.

Palella FJ Jr, Cole SR, Chmiel JS, Riddler SA, Visscher B, Dobs A, Williams C.

Clin Infect Dis. 2004 Mar 15;38(6):903-7. Epub 2004 Mar 1.

PMID:
14999638
49.

Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men.

Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB.

AIDS. 2003 Sep 26;17(14):2035-44.

PMID:
14502006
50.

Impact of HIV infection and HAART on serum lipids in men.

Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA.

JAMA. 2003 Jun 11;289(22):2978-82.

PMID:
12799406

Supplemental Content

Loading ...
Support Center